Meyka Pro banner
Immuron Limited

Immuron Limited Fundamental Analysis (NASDAQ: IMRN)

IMRNNASDAQ
HealthcareBiotechnology
$1.80
$0.69(62.16%)
U.S. Market opens in 7h 5m

Immuron Limited Fundamental Analysis (NASDAQ: IMRN)

Immuron Limited (NASDAQ: IMRN) shows moderate financial fundamentals with a PE ratio of -2.05, profit margin of -63.03%, and ROE of -79.25%. The company generates $0.0B in annual revenue with strong year-over-year growth of 48.63%.

Key Strengths

Cash Position61.60%
PEG Ratio-0.01
Current Ratio7.17

Areas of Concern

ROE-79.25%
Operating Margin-71.07%
We analyze IMRN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -77.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-77.7/100

We analyze IMRN's fundamental strength across five key dimensions:

Efficiency Score

Weak

IMRN struggles to generate sufficient returns from assets.

ROA > 10%
-61.25%

Valuation Score

Excellent

IMRN trades at attractive valuation levels.

PE < 25
-2.05
PEG Ratio < 2
-0.01

Growth Score

Excellent

IMRN delivers strong and consistent growth momentum.

Revenue Growth > 5%
48.63%
EPS Growth > 10%
25.66%

Financial Health Score

Excellent

IMRN maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
7.17

Profitability Score

Weak

IMRN struggles to sustain strong margins.

ROE > 15%
-7924.61%
Net Margin ≥ 15%
-63.03%
Positive Free Cash Flow
No

Key Financial Metrics

Is IMRN Expensive or Cheap?

P/E Ratio

IMRN trades at -2.05 times earnings. This suggests potential undervaluation.

-2.05

PEG Ratio

When adjusting for growth, IMRN's PEG of -0.01 indicates potential undervaluation.

-0.01

Price to Book

The market values Immuron Limited at 1.84 times its book value. This may indicate undervaluation.

1.84

EV/EBITDA

Enterprise value stands at -2.78 times EBITDA. This is generally considered low.

-2.78

How Well Does IMRN Make Money?

Net Profit Margin

For every $100 in sales, Immuron Limited keeps $-63.03 as profit after all expenses.

-63.03%

Operating Margin

Core operations generate -71.07 in profit for every $100 in revenue, before interest and taxes.

-71.07%

ROE

Management delivers $-79.25 in profit for every $100 of shareholder equity.

-79.25%

ROA

Immuron Limited generates $-61.25 in profit for every $100 in assets, demonstrating efficient asset deployment.

-61.25%

Following the Money - Real Cash Generation

Operating Cash Flow

Immuron Limited generates limited operating cash flow of $-5.08M, signaling weaker underlying cash strength.

$-5.08M

Free Cash Flow

Immuron Limited generates weak or negative free cash flow of $-5.09M, restricting financial flexibility.

$-5.09M

FCF Per Share

Each share generates $-0.79 in free cash annually.

$-0.79

FCF Yield

IMRN converts -39.93% of its market value into free cash.

-39.93%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.05

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.84

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.27

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

7.17

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.79

vs 25 benchmark

ROA

Return on assets percentage

-0.61

vs 25 benchmark

ROCE

Return on capital employed

-0.80

vs 25 benchmark

How IMRN Stacks Against Its Sector Peers

MetricIMRN ValueSector AveragePerformance
P/E Ratio-2.0531.74 Better (Cheaper)
ROE-79.25%530.00% Weak
Net Margin-63.03%21584.00% Weak
Debt/Equity0.000.54 Strong (Low Leverage)
Current Ratio7.175.59 Strong Liquidity
ROA-61.25%-90.00% (disorted) Weak

IMRN outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Immuron Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

121.00%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-36.10%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-48.12%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ